跳至主要内容
临床试验/NCT00901290
NCT00901290暂停1 期

A Randomized, Open-Label, Two-way Crossover Study to Determine the Effects of Co-administration of AZD7325 and a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Healthy Female Subjects

AstraZeneca1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
暂停
发起方
AstraZeneca
入组人数
56
试验地点
1
主要终点
To evaluate the effect of repeated doses of AZD7325 on the pharmacokinetics of ORTHO-CYCLEN

研究概览

简要总结

The purpose of this study is to evaluate the effect of repeated doses of AZD7325 on the pharmacokinetics of ORTHO-CYCLEN, a monophasic oral contraceptive

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • If previously pregnant, must be > 6 month post-partum at the time of randomization
  • Body Mass Index (BMI) greater than or equal to 18 and less than or equal to 30 kg/m2

排除标准

  • Use of any prescription medication within 14 days of screening
  • current smoker or history of smoking within the last 3 months prior to enrollment
  • Abnormal pap smear exam result within one year of enrollment.

研究组 & 干预措施

1

Experimental

monophasic oral contraceptive

干预措施: monophasic oral contraceptive (Drug)

2

Experimental

AZD7325

干预措施: AZD7325 (Drug)

结局指标

主要结局

To evaluate the effect of repeated doses of AZD7325 on the pharmacokinetics of ORTHO-CYCLEN

时间窗: weekly

次要结局

  • Characterize the pharmacokinetics of progesterone, luteinizing hormone, follicle-stimulating hormone, and sex hormone binding globulin following dosing with monophasic oral contraceptive (ORTH-CYCLEN) alone and following co-administration with AZD7325(weekly)
  • To characterize the steady-state pharmacokinetics of AZD7325(weekly)
  • To examine the safety and tolerability of AZD7325 in combination with the monophasic oral contraceptive (ORTHO-CYCLEN)(weekly)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Determine the Effects of C-administration of AZD7325... | 临床试验